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Summary.-Two cell lines, one sensitive and one resistant to the cytotoxic effects
of cytosine arabinoside (AraC) were studied in vitro as a drug-resistance model.
The sensitivity of these cell lines, to the effects of free and liposomally trapped
AraC and AraCTP as well as empty liposomes alone and mixed with free drug, was
studied. This was done by following the inhibition of [3H]-dT incorporation into
cellular DNA during exposure to the various drugs and liposomes.
Some of the liposomal-lipid compositions inhibited [3H]-dT incorporation at very
low concentrations, which made them unsuitable for further study. Liposomes
composed of a 7:2:1 molar ratio of phosphatidylcholine:cholesterol:phosphatidic
acid were selected as a suitable non-inhibitory carrier. Sensitivity of the two cell
lines to free AraC differed by 3 logs, when compared in the [3H]-dT-incorporation
assay. The resistant cell line was studied further, and was found to be up to 2 logs
more sensitive to AraCTP when given in liposomes than to either the free drug
alone or mixed with empty liposomes. It appears from these studies that liposomes
are able to help overcome drug resistance in this cell line in vitro.
1-:-D ARABINOFURANOSYL CYTOSINE
(AraC) is one of the most active drugs
used in the treatment of acute leukaemias
(Tattersall, 1977). Its major biochemical
effects have been ascribed to the competi-
tive inhibition of DNA polymerase by
the triphosphate derivative (AraCTP;
Chou et al., 1975). Resistance of tumour
cells to the action ofAraC frequently arises
in patients with leukaemia (Tattersall
et al., 1974) and is believed to be due to a
decrease in the cellular phosphorylation
of AraC to form AraCTP, and/or possibly
increased AraC and arabinofuranosyl cyto-
sine mnonophosphate (AraCMP) deamina-
tion to the inactive arabinofuranosyl-
uridine (AraU) and arabinofuranosyl-
uridine monophosphate (AraUMP) re-
spectively, both leading to a reduction
in the level of AraCTP produced (Tatter-
sall et al., 1974; Coleman et al., 1975).
It is theoretically possible to overcome
this type of resistance to AraC by intro-
ducing the active metabolite AraCTP
directly into resistant cells, e.g. by using
liposomes as carriers.
Liposomes (phospholipid vesicles) were
originally used as model membrane sys-
tems (Bangham et al., 1965) but have
recently been used to entrap a wide
variety of compounds of therapeutic
interest, several reviews of which have
been published (Kimelberg & Mayhew,
1978; Gregoriadis, 1979; Ryman & Tyr-
rell, 1979). There have also been several
reports on the use of liposomes as carriers
ofanti-cancer agents, reviewed by Kaye &
Richardson (1979).
The use of liposomally trapped AraC
against several animal tumours has been
investigated (Mayhew et al., 1976; Rustum
et al., 1979, Ganapathi et al., 1980) with
increased effectiveness over that of the
free drug. This increased the possibility
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that liposomally trapped drugs could be
successfully against drug-resistant tum-
ours. Using liposomally trapped actino-
mycin D, Mayhew et al. (1976) were
able to overcome drug resistance due to
membrane impermeability. Kaye et al.
(1981) using a different drug-resistant
tumour were unable to show any in-
creased effects of liposomally trapped
actinomycin D. Richardson et al. (1979)
and Rustum et al. (1981), using two
AraC-resistant mouse tumours, were un-
able to show any increased effectiveness
of liposomally trapped drugs in over-
coming drug resistance.
We initiated the following investiga-
tions using an AraC-resistant TLX-5
murine lymphoma and the parental AraC-
sensitive cell line to study the effects of
liposomally trapped AraCTP on drug
resistance in this tumour in vitro. We
hoped that liposomes containing the
drug in this phosphorylated form would
be able to overcome drug resistance, thus
proving that liposomes interacted with
and delivered drug into the cells.
MATERIALS AND METHODS
Preparation of [3H]-AraCTP.-[3H]-Ara-
CTP was prepared from [3H]-AraC (Amer-
sham Radiochemicals) by incubation with
L1210 cells in vitro. L1210 cells (3 5 x 107) in
1 ml of RPMI 1640 medium supplemented
with 10% FCS were incubated with 100 ,ul
(15 Ci/mmol) [3H]-AraC ( 6 nmol) for 30
min at 37°C. Cells were centrifuged to a
pellet and the tube inverted to drain off
excess medium. Perchloric acid (50 ,u) was
added and the whole separated by high-
voltage paper electrophoresis, (4 kV for 30
min at 80 mA and pH 3-75). Cold markers for
AraU, AraCMP, arabinofuranosylcytosine
diphosphate (AraCDP), and AraCTP were
used at the same time. The product obtained
was 25% AraCTP, 2% AraCMP and 1%
AraCDP. The remaining 72% was unchanged
AraC. There was no AraU because L1210
contains no cytidylate deaminase. The [3H]-
AraCTP was eluted in distilled water and
freeze-dried.
Tumour ce1t8.-Two cell lines were studied.
One was sensitive to AraC and the other
resistant; both were from mouse lymphoma
TLX-5. The resistant cell line was derived
from the sensitive parent line by tumour
passage in mice treated with progressively
increasing doses of AraC. Both lines were
provided by Dr T. A. Connors, then at the
Chester Beatty Institute of Cancer Research.
The AraC-sensitive cell line was grown in
Dulbecco's medium containing 10% FCS,
antibiotics and bicarbonate, and were gassed
with 95% air, 5% CO2. The AraC-resistant
cell line was passaged in CBA mice at weekly
intervals by dilution of the ascites fluid
1:10 Hank's buffered salt solution (HBS)
and i.p. injection of0.1 ml of the cell suspen-
sion.
For in vitro study, the resistant cell line
was harvested and washed twice with HBS.
Erythrocytes were removed by flash lysis,
by resuspending the cell pellet in 5 ml of
distilled water followed 30 sec later by
adding 5 ml of double-strength saline. Cells
were then centrifuged and resuspended in
HBS, counted and diluted to 2 x 106 cells/ml
in HBS. The sensitive cell line was harvested
by centrifugation from culture medium
and was also washed and diluted to 2 x 106
cells/ml in HBS.
Preparation of liposomes.-Liposomes were
prepared from various combinations of
phosphatidylcholine (egg lecithin, PC) pre-
pared by the method of Dawson (1958),
cholesterol (C, Sigma), phosphatidic acid
(PA, Lipid Products), stearylamine (SA)
and dicetylphosphate (DCP, K & K Labs,
New York.
Five mg of lipid in chloroform were rotary-
evaporated at 37°C under vacuum to form a
dry lipid film. To this film was added 2-5 ml
of Dulbecco's PBS, either alone or containing
AraC or AraCTP at various concentrations,
but both containing trace amounts of their
tritiated components. Each batch ofliposomes
was then sonicated, using an exponential
titanium probe, for 4 x 15 sec with cooling
between in an ice bath. A 120W sonicator was
used at an energy setting of 6-8 ,um peak-to-
peak. Trapped drug levels were then deter-
mined by passage through a Sephadex G50
column at 4°C. Most of the studies made
were with liposomes composed of PC:C:PA
in a 7:2: 1 molar ratio: entrapment of
AraCTP in these was 0.4% of the total
added. Liposomes used for in vitro studies
were sterilized by passage through a 0 45,um
sterile filter and were kept on ice until used
later that day.
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[3H]-dT-incorporation assay and lipid
sen8itivity.-A method similar to that of
Curt et al. (1976) was used. Several different
lipid compositions were used in this study to
determine their effects on [3H]-dT incorpora-
tion into cellular DNA. 106 cells in 0 5 ml
of HBS were added in triplicate to 0 5 ml of
liposome suspension in Dulbecco's PBS. The
cells were then incubated with shaking in an
atmosphere of 5% CO2 and air for various
intervals at 37°C, followed by addition of
1 ,uCi [3H]-dT (46 Ci/mmol) and 30 min
later 0 5 ml of 1 OmM ice-cold dT was added
and the tubes put into ice. Cells were then
filtered on to Whatman GFC filters and
washed x 3 with 5% trichloroacetic acid
and twice with ethanol, and then allowed to
dry at 37°C. [3H]-dT incorporation was then
determined by scintillation counting. All
results of labelled dT incorporation were
expressed as a percentage of the controls
not exposed to lipid. Cell clumping and pH
changes were minimized by gently shaking
in the 5% CO2 atmosphere. Viability of
control groups at the end of the incubation
was never below 90%.
AraC 8en8itivity of the 2 cell line8.-The
sensitivity of the 2 cell lines was determined
as follows: triplicate samples of 106 cells in
0 5 ml of HBS were incubated with various
dilutions of AraC to give a total volume of
1-0 ml, for various intervals. Estimation of
[3H]-dT incorporated into cellular DNA was
as described above. Results are shown in
Fig. 2.
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Sen8itivity of the AraC-resistant cell line to
free and entrapped drugs.-The sensitivity of
the AraC-resistant cell line to liposomally
trapped AraC and AraCTP as well as free
AraCTP and a mixture of free AraCTP with
empty liposomes was tested using the
[3H]-dT-incorporation assay described above.
Liposomes composed of a 7:2:1 molar ratio
of PC:C:PA were used. It is essential to
point out here that all liposome preparations
were used without separation from the free
drug used in their preparation. This was to
ensure more reproducible conditions and
simplify the methodology. This also necessi-
tated the use of the free drug plus empty
liposome control.
RESULTS
Fig. 1 shows the results of various
liposome lipid compositions on the inhibi-
tion of [3H]-dT incorporation into DNA
of the AraC-sensitive cell line. Similar
results were also obtained with the
AraC-resistant cell line (data not shown).
Cationic liposomes composed of a 7:2:1
molar ratio of PC:C:SA and anionic
liposomes with a 7: 2: 1 molar ratio of
PC:C:DCP both inhibited [3H]-dT incor-
poration into the cell lines at lipid con-
centrations as low as 2-5 ,g/ml. Because
of this inhibitory effect, these two lipid
compositions were not used further in our
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FIG. 1.-Effects of 3 liposome lipid compositions on [3H]dT incorporation into DNA of the AraC-
sensitive TLX-5 cell line. Values are means of triplicate samples. A= 7: 2: 1 molar ratio PC:C:SA;
B = 7: 2: 1 molar ratio PC:C:DCP; C = 7: 2: 1 molar ratio PC:C:PA. Final concentration (mg/ml)
of lipid in the incubation mixture D2 = 2 *5; * =0 *25; A=0
-025; 0 = O 0025.
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FIG. 2.-Effect of AraC on the [3H]dT incorporation into DNA of the AraC-sensitive and resistant
TLX-5 cell lines. Values are means +s.d. * =sensitive; * =resistant. Exposure to AraC: A = h;
B=2 h; C=3 h.
studies. By contrast, liposomes of a
7:2:1 molar ratio of PC:C:PA had little
or no inhibitory effects up to concentra-
tions of 2-5 mg/ml, and that only after
3h incubation.
Fig. 2 shows the response of the AraC-
sensitive and resistant cell lines to the
inhibitory effects ofvarious concentrations
of AraC after 1, 2, and 3h incubation
before pulse-labelling with [3H]-dT. The
AraC-sensitive cell line showed the greatest
inhibition of [3H]-dT incorporation into
DNA, with ID50 values for 1, 2, and 3h of
500, 20, and 7 nm respectively. In
marked contrast, the resistant line showed
significant inhibition only after 3h ex-
posure to AraC, and had an ID50 value
of 10 piM, which means that the sensitive
cell line was more than 1400 times more
sensitive to AraC than the resistant line.
Fig. 3 shows the results from one
experiment comparing the liposomal pre-
paration of AraCTP with free AraCTP
and free AraCTP mixed with empty
liposomes, in the AraC-resistant cell line
only. The liposomally trapped AraCTP
showed a greater inhibition of [3H]-dT
incorporationinto DNAthan freeAraCTP.
Although this effect appeared to be quite
variable between experiments, presum-
ably due to variations in liposome pre-
parations or the tumour cells, it was quite
conclusive that the liposomal form of
AraCTP was a more effective inhibitor
of [3H]-dT incorporation than free Ara-
CTP. This was especially so when one
considered that no difference was detected
between free AraCTP and other controls
(including free AraC, liposomally trapped
AraC, and free AraCTP mixed with
empty liposomes) in 5 separate experi-
ments. Of these 5 comparisons of free
and liposomally trapped AraCTP in the
AraC-resistant cell line, 4 showed greater
inhibition of [3H]-dT incorporation by
liposomal AraCTP, whilst the fifth showed
no difference. The greatest difference
between the ID50 values of the free and
entrapped drug was 200-fold (20 ,uM for
the free and 0-1 pM for the entrapped).
The data shown in Fig. 3 are from an
experiment with a 1-0,um ID50 for lipo-
somal AraCTP and 20p,M ID50 for the
free drug. The liposomal form of AraCTP
was therefore effective in overcoming
AraC resistance in vitro.
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FIG. 3. Effect of free AraCTP (*), free
AraCTP mixe(l with empty liposomes (U)
and liposomally trappe(t AraCTP ( L) on
the [3H]dT incorporation into the D)NA of
TLX-5 AraC-resistant cells after 3-5 h
incubation. Values are means of triplicate
samples. The liposomes contain mg/ml
of lipid in the PC: A: PA molar ratio 7: 2: 1.
0.4% of the free drtug is trappe(d in the
liposomes.
DISCUSSION
We have shown that the [3H]-dT-
incorporation assay for the measurement
of drug effects was very sensitive to the
type of lipid used in the preparation of
the liposomes added to the incubation
medium. We and other workers have
shown that several lipids are toxic in
vitro (Tyrrell et al., 1977; Layton et al.,
1980; Campbell, 1980) and in vivo (Bruni
et al., 1976; De Barsey et al., 1976; Adams
et al., 1977; Steger & Desnick, 1977).
Liposome toxicity must be considered
when making any measurements involv-
ing the use of liposomes. The 2 compon-
ents believed to be responsible for the
inhibition of dT incorporation into DNA
in the assay system are stearylamine and
dicetylphosphate. Liposomes containing
phosphatidic acid as the charged compon-
ent had little or no inhibitory effect on dT
incorporation.
The ID50 for the effects of AraC on the
drug-sensitive and drug-resistant cell lines
differs by at least 3 logs (see Fig. 2). A
drug-resistant cell line offers a means of
investigating the mechanism(s) of action
of liposomally trapped drug, by eliminat-
ing the confusing side effects produced by
free drug in the liposomal preparation,
or the leakage of drug during incubation.
To date we are unable to say whether
the resistant cell line used in these studies
was resistant to AraC because ofdecreased
deoxycytidine kinase levels, enhanced
deoxycytidine deaminase and/or deoxy-
cytidylate deaminase levels or to some
other possible mechanism. We could be
certain, however, that resistance to AraC
was not due to a permeability defect. Not
only would this be improbable (see
Mulder & Harrap, 1975), but our results
with liposomally trapped AraC showed
no greater inhibition of DNA synthesis
than those with free AraC. Other workers
have suggested that it is most probable
that AraC resistance develops through
changes in the level(s) of one or more of
the three enzymes described above (Tat-
tersall et al., 1974; Coleman et al., 1975).
The sensitivity of the drug-resistant cell
line to the liposomal form of AraCTP
indicates that the liposomes are able to
introduce their contents intracellularly in
an active form capable of inhibiting
DNA synthesis. However, there is a
considerable difference between the ID50
for AraC in the drug-sensitive cell line
(7 0 nM), and the ID50 for liposomally
trapped AraCTP in the drug-resistant
cell line (0-1-1-0 EM). This may be due to
the low level of drug trapped in the
liposomes (0.4%o) and possibly the low
uptake of liposome by the cells.
The variations in liposomal AraCTP
sensitivity found for the resistant cell
line were most probably duie to variations
in the batches of cells used. We had to
grow the resistant cells in vivo and
harvest the cells from ascitic fluid when
required for experiment. These cells varied
from week to week with respect to con-
taminating blood cells. The poorest results
were obtained when there was the highest
level of erythrocyte contamination, with
cell preparation requiring 3 cycles of
osmotic lysis for their removal. The
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best results were from batches of cells
requiring only a single lysis to remove
contaminating erythrocytes.
It appears from the data that lipo-
somes are capable of acting as drug
carriers, and that liposomal AraCTP is
effective in overcoming the AraC-resis-
tance of the TLX-5 resistant cell line
in vitro. It now remains to test these cells
in mice, to see whether it is still possible
to overcome AraC resistance in this way.
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